Cécile Réal

Cécile is an experienced entrepreneur in medical industry and management of start-ups. She co-founded her first start’up at the age of 25, Bioprofile, developing innovative solutions for arthritis. She rapidly expanded the company and gained strong experience in product development, business development and fund raising. She also set up an international distribution network and integrated Bioprofile within a US SME, before being acquired by a larger company. She has then co-founded Fluoptics and served as Interim CEO at Inatherys, two start’ups developing imaging solutions and a new drug to treat cancer.

In 2011, Cecile co-founded Endodiag specialized in endometriosis diagnosis and Medevice Capital, an entrepreneur seed fund specialized in medical device. She is passionate by innovation, impact and entrepreneurship and dedicates part of her time to mentor women entrepreneur.

Cécile has been nominated Women Entrepreneur of the Year by France Biotech (2016), EU Women entrepreneur by the European commission (2016) and jury President of the Ilab competition 2022 (French National Innovation competition).

About Endodiag

Endodiag is an innovative biotechnology company fully dedicated to the development of new solutions to improve the diagnosis of endometriosis. Endometriosis is a disease that causes causing unbearable pain and infertility and that affects 180 million women worldwide. It can only be diagnosed by a surgery and take an average.

Medevice Capital is a seed-fund dedicated to medical devices and e-health. Medevice Capital is driven by entrepreneurs, invests in early-stage company and actively helps them to grow. Medevice motto is “Smart ideas for big impact”.